| Aug 21 |
FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
|
| Aug 13 |
BioCardia, Inc. (BCDA) Q2 2024 Earnings Call Transcript
|
| Aug 13 |
BioCardia GAAP EPS of -$0.08 beats by $0.02, revenue of $0.03M misses by $0.02M
|
| Aug 13 |
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
|
| Aug 7 |
BioCardia to Host Q2 2024 Corporate Update and Financial Results Conference Call on August 13, 2024
|
| Jul 30 |
BioCardia Submits for FDA Approval of Morph® DNA™ Steerable Introducer Product Family
|
| Jul 25 |
Patient Enrollment Commenced in Pivotal Phase 3 Trial of CardiAMP Cell Therapy for the Treatment of Ischemic Heart Failure
|
| Jul 17 |
BioCardia Announces United States Patent Issuance on Morph DNA Multi-Directional Steerable Catheter Transseptal Application
|
| Jul 8 |
CellProthera and BioCardia Collaborate on Successful Phase II Trial of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction
|
| Jun 10 |
Why KKR Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket
|
